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A B S T R A C T
Methionine adenosyltransferase (MAT) I/III deficiency is an inborn error of metabolism caused by mutations in
MAT1A, encoding the catalytic subunit of MAT responsible for the synthesis of S-adenosylmethionine, and is
characterized by persistent hypermethioninemia. While historically considered a recessive disorder, a milder
autosomal dominant form of MAT I/III deficiency occurs, though only the most common mutation p.Arg264His
has ample evidence to prove dominant inheritance. We report a case of hypermethioninemia caused by the
p.Ala259Val substitution and provide evidence of autosomal dominant inheritance by showing both maternal
inheritance of the mutation and concomitant hypermethioninemia. The p.Ala259Val mutation falls in the dimer
interface, and thus likely leads to dominant inheritance by a similar mechanism to that described in the pre-
viously reported dominant negative mutation, that is, by means of interference with subunits encoded by the
wild-type allele.
1. Introduction
Methionine adenosyltransferase I/III (MATI/III) deficiency (MIM
#250850) is the most common cause of hereditary persistent elevation
of methionine and occurs from mutations in MAT1A. Isolated elevation
of methionine without elevation of homocysteine, thus excluding cy-
stathionine β-synthase deficiency, was first noted in 1974 with the
advent of newborn screening by dried blood spot analysis [1]. Based on
newborn screening data the incidence of isolated elevation of methio-
nine is variable, depending on the geographic region: a study of a
Taiwanese population showed 16 cases of isolated hypermethioninemia
out of 1,701,591 newborns, of whom more than half had mutations in
MAT1A [2]. On the other hand, two other studies from populations in
the Iberian peninsula showed an incidence of 1/28,163 and 1/26,000 in
Galicia and Portugal, respectively [3,4]. The disorder can be inherited
in an autosomal either dominant or recessive manner. The recessive
form may be characterized by central nervous system abnormalities,
mainly manifested by white matter changes on brain MRI, which were
found in 32 of 64 patients with either homozygous or compound
heterozygous mutations [5]. Dominant inheritance of hypermethioni-
nemia was first described in 1992 [6], and was subsequently identified
to be caused by theMAT1A p.Arg264His mutation [7,8]. This dominant
form is considered benign, with only mild elevations in methionine
concentrations [9]. In the aforementioned Galician series, all patients
detected through newborn screening were heterozygous for the p.Ar-
g264His mutation [3]. Indeed, this dominant mutation causes the ma-
jority of cases of hypermethioninemia detected by newborn screening
[10]. Notably, the p.Arg264His mutation has also been seen in com-
pound heterozygotes with recessive disease, both with and without
neurologic abnormalities [5] and a single heterozygote was reported to
have myelination abnormalities [4].
The MAT enzyme (EC2.5.1.6) can be dimeric (MAT III) or tetra-
meric (MAT I), and the homodimerization is essential to its enzymatic
activity [2]. It has two main functions, S-adenosylmethionine (AdoMet)
synthesis and tripolyphosphatase (PPPase) activity. In a two-step re-
action, the adenosyl group of ATP is transferred to methionine forming
AdoMet and tripolyphosphate (PPPi), and then without dissociating
from the enzyme, the PPPi is enzymatically hydrolyzed to release
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pyrophosphate and phosphate. AdoMet is the primary methyl group
donor for a wide range of biological processes as well as having func-
tions in polyamine synthesis and regulation of the methionine/homo-
cysteine cycle [11]. Initial investigations into the autosomal dominant
form of MATI/III deficiency caused by the p.Arg264His variant showed
it interferes with the ability of MAT subunits to form homodimers [7]. It
has been shown that the p.Arg264His variant results in an enzyme with
0.37% of AdoMet synthetic activity in rats [9]. On the other hand, MAT
PPPase activity was similar to wild-type (WT), and was inhibited by
inorganic pyrophosphate but not stimulated by methionine or ATP,
suggesting deficient binding of substrates [9].
Other series have reported heterozygous changes in MAT1A in pa-
tients with isolated hypermethioninemia [9,11,12], although the pat-
tern of inheritance for these other variants has never been clarified.
Until recently, it was assumed either that the second variant in MAT1A
was never found, or the possibility of a second mutation associated with
autosomal dominant inheritance was entertained, but never confirmed,
due to lack of parental testing. Recently, additional heterozygous MA-
T1A mutations have been described, particularly p.Arg249Gln (6 pa-
tients) and p.Gly280Arg (1 patient) are also located near the dimeric
interface [13]. The fathers of two of the patients with the p.Arg249Gln
mutation also carried the substitution and had mildly elevated plasma
methionine levels. Herein we describe a case of a mother and daughter
with hypermethioninemia, both carrying the p.Ala259Val mutation,
thus providing confirmation for the autosomal dominant inheritance of
this variant.
2. Materials and methods
The manuscript is a retrospective case report that does not require
ethics committee approval at our institution. No identifiable patient
information is provided in the manuscript.
2.1. Biochemical assays
Plasma AdoMet and AdoHcy were measured by tandem mass
spectrometry (Shimadzu Nexera LC System interfaced with a 5500
QTRAP® Sciex) as previously described [14]. Plasma amino acids were
quantitated by cation-exchange chromatography with post-column
ninhydrin derivatization using a Biochrom amino acid analyzer.
2.2. Molecular testing
Genomic DNA was extracted from the patient's blood and the
TruSight One kit (v1.0) was used to target the exon regions of genes.
These targeted regions were sequenced using the NextSeq 500 se-
quencing system with 150 bp paired-end reads. The DNA sequence was
mapped to, and analyzed in comparison with, the published human
genome build UCSC hg19 reference sequence. The targeted coding
exons and splice junctions of the known protein-coding RefSeq genes
were assessed for the average depth of coverage of 10× and data
quality threshold values of 95%. All reportable sequence variants were
confirmed by independent Sanger sequence analysis.
Fig. 1. A) Proband's plasma methionine concentration over time. B) Next-generation sequencing short read alignments to the reference sequence for the proband. C) Chromatogram of
Sanger sequencing for the proband, mother, and father (top, middle, and bottom respectively). D) Human methionine adenosyltransferase III (dimer), with the p.Ala259 residue
highlighted in green showing its position at the dimer interface. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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2.3. Protein modeling
Visualization of the mutation within the 3-dimensional protein
structure was achieved by iCn3D [15] by uploading a PDB-format file
containing structural information for human MAT I. This file (PDB ID:
2OBV) was downloaded from the RCSB Protein Data Bank [16]; the
crystal structure for the model had been determined using X-ray dif-
fraction.
3. Case report and results
The patient presented at 3 weeks of age for evaluation after a
newborn screen was positive for elevated methionine. She was born at
40 weeks of gestation by spontaneous vaginal delivery. Birth weight
was 3.205 kg. She was breast milk and formula fed. Her newborn screen
on day of life 1 showed methionine concentration of 0.81 mg/dL
(54 μmol/L) for a cut-off of< 0.8 mg/dL, and repeat sample collected
at 16 days of life showed a methionine concentration of 1.08 mg/dL
(73 μmol/L). Initial homocysteine was 8.4 μmol/L (reference range
2.9–11.8). Molecular testing for genes in the methionine pathway
identified a heterozygous variant in MAT1A. At follow up at 5 months
and subsequently at 17 months of age, she was doing well concerning
growth and development. No remarkable abnormalities were noted on
examination.
The patient's plasma methionine concentration was 175, 185, 192,
136, 75 μmol/L (reference range 9–43 μmol/L) at ages 3.5 weeks,
2 months, 3 months, 5 months, and 12 months, respectively (see
Fig. 1A). There were no other abnormalities on plasma amino acid
chromatography including no elevation in tyrosine. The S-adeno-
sylmethionine was 90 nmol/L (reference range 33–95) and the S-ade-
nosylhomocysteine was 24 nmol/L (reference range 13–28). She had
intermittently elevated alanine aminotransferase (68 and 88 units/L at
2 and 5 months of age, reference ranges 26–61 and 26–51 units/L re-
spectively) with normal aspartate aminotransferase, alkaline phospha-
tase, and total bilirubin. The patient was found to be heterozygous for
the c.776C > T (p.Ala259Val) variant in MAT1A (NM_000429.2; see
Fig. 1B and C). A bioinformatics algorithm to identify exon-level copy
number changes directly from the sequencing data did not predict any
deletion or duplication in the gene. This mutation falls in the dimer-
ization interface of the enzyme (see Fig. 1D).
The p.Ala259Val variant is maternally inherited. The patient's mo-
ther had mild elevation of methionine of 50 μmol/L (normal range
10–42) at 27 years of age, while her repeat plasma amino acid profile at
28 years old showed normal methionine at 33 μmol/L. On both occa-
sions, her transaminases were normal, although she did have a history
of elevated liver enzymes as a child including a hepatitis-like illness,
which lasted months.
4. Discussion
The p.Ala259Val mutation is exceedingly rare; no nonsynonymous
missense variants were seen at the p.Ala259 position in 123,136
exomes in the gnomAD database [17]. Three patients were previously
reported to carry a heterozygous p.Ala259Val variant in MAT1A, al-
though the authors specifically mentioned that the pattern of in-
heritance could not be clarified since parents were not tested [2,12].
Fernández-Irigoyen et al. [11] demonstrated approximate 80% reduc-
tion of the MAT activity in the p.Ala259Val mutant in comparison to
WT while PPPase activity remained over 80% of WT levels. Ala259 is
situated in the flexible loop, a highly conserved block in the MAT gene,
hypothesized to regulate the entrance and positioning of methionine to
the active site [18,19]. Other mutations in the loop show similar
changes in enzyme activity [11]. Another report suggested that the
Ala259Val variant might affect the dimerization interface [20]. The
first patient reported with the p.Ala259Val mutation had initial Met
level of 204.5 μmol/L with a subsequent average of 37 μmol/L, and had
verbal, performance, and full scale IQs of 67, 72, and 61 respectively
[2]. The second and third patients were siblings with identical muta-
tions but varying patterns of methionine elevation (patient 1 and 2 both
had a methionine concentration of 64.3 μmol/L on newborn screen,
209.8 μmol/L and 112.8 μmol/L at first visit, respectively, and a mean
of 138.8 μmol/L and 88.75 μmol/L, respectively) [12].
Our patient's methionine levels were persistently elevated but did
show evidence of decline with age. Her mother, also a heterozygote for
the mutation, had mild hypermethioninemia. These findings provide
evidence that heterozygosity for the p.Ala259Val mutation in MAT1A
accounts for a second variant causative of autosomal dominant hy-
permethioninemia. The common p.Arg264His mutation has been
shown to have less marked elevations in methionine with age [3,11], a
pattern that has since been shown in patients with other heterozygous
mutations [12]. Indeed, a case series of 9 such patients reported that
none of the patients had symptoms of MATI/III deficiency, all had
normal development, tolerated normal diets, and had similar patterns
of methionine levels that trended downward on follow-up [12]. Simi-
larly, 6 patients with p.Arg248Gln and 1 patient with p.Gly280Arg in
the heterozygous state had methionine levels that declined over time
[13]. Both of these residues are predicted to be located at the dimer-
ization interface. Our results align with this pattern, in that our patient's
methionine seems to be decreasing over time and her mother's was only
slightly elevated in one instance. The reason for the downward trend of
methionine levels in dominant MATI/III deficiency is unclear. One
hypothesis is total protein (and therefore methionine) intake in infancy
with typical volumes of human milk intake are higher than estimated
need for growth [21], and that when solid food intake increases and
milk intake decreases between 6 and 12 months of age this imbalance
normalizes.
Both the patient and her mother had elevated transaminases, mild
in the child's case and severe though transient in the mother's child-
hood. While mildly abnormal hepatocyte morphology on electron mi-
croscopy has been described in several patients [22,23,24] and MAT1A
knockout mice develop steatohepatitis and have a high incidence of
hepatocellular carcinoma [25,26], the majority of patients with MATI/
III deficiency have no biochemical evidence of liver dysfunction [5].
The patient's plasma total homocysteine was normal which is expected,
though slight elevations of homocysteine can be seen in severe MATI/III
deficiency [27,28].
There are two potential mechanisms for the deleterious effect of this
mutation. The Ala259 residue is located in the dimerization interface of
the protein [20], and just like the previously described dominant mu-
tation, would be predicted to act in a dominant negative fashion by
interfering with the dimerization (MAT III) or tetramerization (MAT I)
of the enzyme. Other authors localize the residue to a flexible loop that
is responsible for positioning and entry of methionine into the active
site of the enzyme [11,18,19]. However, the inability to bind methio-
nine is unlikely to explain the dominant inheritance, since the wild-type
subunit would have enough activity to utilize methionine for AdoMet
synthesis. However, an impairment in polymerization can indeed ac-
count for dominant inheritance by means of interference with the wild-
type enzyme–as has been previously experimentally shown [7]–since
only the polymeric enzyme is active.
In summary, we provide confirmation that the p.Ala259Val muta-
tion in MAT1A is also responsible for autosomal dominant hy-
permethioninemia, and given its position at the dimerization interface,
likely through a dominant negative effect, as with the previously re-
ported dominant mutation.
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